Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors
Year: 2021
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Institutions: Emory University, City Of Hope National Medical Center, City of Hope, Duke University, Duke Medical Center, Washington University in St. Louis, Alvin J. Siteman Cancer Center, Memorial Sloan Kettering Cancer Center, Yale Cancer Center, Yale University, UC Davis Comprehensive Cancer Center, University of California, Davis, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Mary Crowley Cancer Research Center, Herbert Irving Comprehensive Cancer Center, Columbia University, Norwalk Hospital, Nuvance Health, University of Cincinnati, Amgen (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4200195771